influencia sobre la recidiva en el cáncer vesical superficial - Redalyc
influencia sobre la recidiva en el cáncer vesical superficial - Redalyc
influencia sobre la recidiva en el cáncer vesical superficial - Redalyc
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
42<br />
CONCLUSIONES<br />
Hemos llegado a <strong>la</strong>s sigui<strong>en</strong>tes conclusiones:<br />
1. La frecu<strong>en</strong>cia de empleo de tratami<strong>en</strong>to <strong>en</strong>do<strong>vesical</strong><br />
se increm<strong>en</strong>tó <strong>en</strong> nuestro estudio de acuerdo al<br />
grado de malignidad. Fue significativam<strong>en</strong>te más alta<br />
<strong>en</strong> paci<strong>en</strong>tes con tumores de alto grado o pres<strong>en</strong>cia<br />
de Tis, <strong>en</strong> los que se usó fundam<strong>en</strong>talm<strong>en</strong>te BCG.<br />
2. La terapia fue poco empleada <strong>en</strong> los tumores de<br />
bajo grado, y <strong>en</strong> los tumores de grado intermedio<br />
<strong>la</strong> probabilidad de no seguir tratami<strong>en</strong>to <strong>en</strong>do<strong>vesical</strong><br />
fue simi<strong>la</strong>r a <strong>la</strong> de emplear<strong>la</strong>, estando basada prefer<strong>en</strong>tem<strong>en</strong>te<br />
<strong>en</strong> quimioterapia con Mitomicina C.<br />
3. El porc<strong>en</strong>taje de paci<strong>en</strong>tes que recibió tratami<strong>en</strong>to<br />
intra<strong>vesical</strong> de mant<strong>en</strong>imi<strong>en</strong>to fue estadísticam<strong>en</strong>te<br />
superior <strong>en</strong> caso de multiplicidad, pero no se re<strong>la</strong>cionó<br />
con <strong>el</strong> estadio, grado ni con <strong>el</strong> tamaño tumoral.<br />
4. El empleo de insti<strong>la</strong>ciones <strong>vesical</strong>es increm<strong>en</strong>tó de<br />
forma indep<strong>en</strong>di<strong>en</strong>te <strong>el</strong> tiempo hasta <strong>la</strong> <strong>recidiva</strong>. Se<br />
demostró que <strong>la</strong> recurr<strong>en</strong>cia se produjo significativam<strong>en</strong>te<br />
más tarde cuando se habían empleado dosis<br />
altas de BCG y terapia de mant<strong>en</strong>imi<strong>en</strong>to.<br />
BIBLIOGRAFÍA y LECTURAS<br />
RECOMENDADAS (*lectura de interés y **<br />
lectura fundam<strong>en</strong>tal)<br />
*1.<br />
*2.<br />
3.<br />
4.<br />
5.<br />
**6.<br />
LAGUNA, M.P.; VICENTE, J.: “Cirugía <strong>en</strong>doscópica<br />
de <strong>la</strong> vejiga. Tratado de <strong>en</strong>dourología”.<br />
Pulso Ediciones. Capitulo 4:236. 1996.<br />
ANDIUS, P.; DAMM, O.; HOLMANG, S.:<br />
“Prognostic factors in pati<strong>en</strong>ts with carcinoma<br />
in situ treated with intra<strong>vesical</strong> bacille Calmette-<br />
Guerin”. Scand. J. Urol. Nephrol.,38:285, 2004.<br />
TAKASHI, M.; WAKAI, K.; HATTORI, T. y<br />
cols.: “Multivariate evaluation of factors affecting<br />
recurr<strong>en</strong>ce, progression, and survival in pati<strong>en</strong>ts<br />
with <strong>superficial</strong> b<strong>la</strong>dder cancer treated with intra<strong>vesical</strong><br />
bacillus Calmette-Guerin (Tokyo 172 strain)<br />
therapy: significance of concomitant carcinoma<br />
in situ”. Int. Urol. Nephrol.;33:41, 2002.<br />
LAMM, D.L.: “Efficacy and safety of bacille<br />
Calmette-Guerin immunotherapy in <strong>superficial</strong><br />
b<strong>la</strong>dder cancer”. Clin. Infect. Dis.;31:86, 2000.<br />
BRAKE, M.; LOERTZER, H.; HORSCH, R. y<br />
cols.: “Long-term results of intra<strong>vesical</strong> bacillus<br />
Calmette-Guerin therapy for stage T1 <strong>superficial</strong><br />
b<strong>la</strong>dder cancer”. Urology. ;55:673,2000.<br />
OOSTERLINCK, W.: “Guid<strong>el</strong>ines on diagnosis<br />
and treatm<strong>en</strong>t of <strong>superficial</strong> b<strong>la</strong>dder cancer”. Minerva<br />
Urol. Nefrol.;56:65, 2004.<br />
J. García Rodríguez, J. M. Fernández Gómez, S. Escaf Barmadah y cols.<br />
*7.<br />
8.<br />
9.<br />
10.<br />
11.<br />
*12.<br />
**13.<br />
14.<br />
15.<br />
16.<br />
LAMM, D.L.; BLUMENSTEIN, B.A.; CRISS-<br />
MAN, J.D. y cols.: “Maint<strong>en</strong>ance bacillus Calmette-Guerin<br />
immunotherapy for recurr<strong>en</strong>t TA,<br />
T1 and carcinoma in situ transitional c<strong>el</strong>l carcinoma<br />
of the b<strong>la</strong>dder: a randomized Southwest Oncology<br />
Group Study”. J. Urol. ;163:1124, 2000.<br />
STARTSEV, V.; POULINE, I.: “Adjuvant therapy<br />
in differ<strong>en</strong>t risk-groups of pati<strong>en</strong>ts with <strong>superficial</strong><br />
b<strong>la</strong>dder cancer”. Arch. Ital. Urol. Androl. ;77:93,<br />
2005.<br />
PEYROMAURE, M., GUERIN, F.; AMSE-<br />
LLEM-OUAZANA, D. y cols.: “Intra<strong>vesical</strong> bacillus<br />
Calmette-Guerin therapy for stage T1 grade<br />
3 transitional c<strong>el</strong>l carcinoma of the b<strong>la</strong>dder: recurr<strong>en</strong>ce,<br />
progression and survival in a study of 57<br />
pati<strong>en</strong>ts”. J. Urol. ;169:2110, 2003.<br />
PAWINSKY, A., SYLVESTER, R., KURTH,<br />
K.H. y cols.: “A combined Analisys of European<br />
Organization for Research and Treatm<strong>en</strong>t of Cancer,<br />
and Medical Research Council randomized<br />
clinical trials for the prophy<strong>la</strong>ctic treatm<strong>en</strong>t of<br />
stage TaT1 b<strong>la</strong>dder cancer. European Organization<br />
for Research and Treatm<strong>en</strong>t of Cancer G<strong>en</strong>itourynary<br />
Tract Cancer Cooperative Group and<br />
the Medical Research Council Working Party on<br />
Superficial B<strong>la</strong>dder Cancer”. J. Urol ;156:1934.<br />
1996.<br />
HISATAKI, T.; MIYAO, N.; NASUMORI, N. y<br />
cols.: “Risk factors for multiple intra<strong>vesical</strong> recurr<strong>en</strong>ces<br />
of <strong>superficial</strong> b<strong>la</strong>dder cancer”. Urology ;<br />
58: 935, 2001.<br />
SYLVESTER, R.J.; OOSTERLINCK, W.; VAN<br />
DER MEIJDEN, A.P.: “A single immediate postoperative<br />
instil<strong>la</strong>tion of chemotherapy decreases<br />
the risk of recurr<strong>en</strong>ce in pati<strong>en</strong>ts with stage Ta<br />
T1 b<strong>la</strong>dder cancer: a meta-analysis of publishedresults<br />
of randomised clinical trials”. J. Urol. ;<br />
171:2186, 2004.<br />
BOHLE, A.; BOCK, P.R.: “Intra<strong>vesical</strong> bacille<br />
Calmette-Guerin versus mitomycin C in <strong>superficial</strong><br />
b<strong>la</strong>dder cancer: formal meta-analysis of comparative<br />
studies on tumor progression”. Urology<br />
;63:682, 2004.<br />
BOHLE, A.; JOCHAM, D.; BOCK, P.R.: “Intra<strong>vesical</strong><br />
bacillus Calmette-Guerin versus mitomycin<br />
C for <strong>superficial</strong> b<strong>la</strong>dder cancer: a formal<br />
meta-analysis of comparative studies on recurr<strong>en</strong>ce<br />
and toxicity”. J. Urol. ;169:90, 2003.<br />
SHELLEY, M.D.; WILT, T.J.; COURT, J. y cols.:<br />
“Intra<strong>vesical</strong> bacillus Calmette-Guerin is superior<br />
to mitomycin C in reducing tumour recurr<strong>en</strong>ce in<br />
high-risk <strong>superficial</strong> b<strong>la</strong>dder cancer: a meta-analysis<br />
of randomized trials”. BJU Int.;93:485, 2004.<br />
CLARKE, N.S.; BASU, S.; PRESCOTT, S. y cols:<br />
“Chemo-prev<strong>en</strong>tion in <strong>superficial</strong> b<strong>la</strong>dder cancer<br />
using mitomycin C: a survey of the practice patterns<br />
of British urologists”. BJU Int.;97:716, 2006.